Pacific Bio (PACB) Tops Q2 EPS by 3c

Pacific Bio (NASDAQ: PACB) reported Q2 EPS of ($0.13), $0.03 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $20.6 million versus the consensus estimate of $17.2 million.

For earnings history and earnings-related data on Pacific Bio (PACB) click here.

You May Also Be Interested In

• Nvidia pitches Vera CPU to Chinese clients with August delivery target
• Carvana (CVNA) PT Lowered to $85 at RBC Capital
• UBS Reiterates Neutral Rating on Lennar (LEN) Following Q2 Results